Abbot Targets Amneal In Latest Suit Over Generic Niaspan

Law360, New York (February 29, 2012, 5:10 PM EST) -- Abbott Laboratories on Monday fired off the latest in a series of suits defending its cholesterol drug Niaspan in Delaware federal court, aiming to block Amneal Pharmaceuticals LLC from producing a generic version of the drug.

Abbot claims both New York-based Amneal Pharmaceuticals and its Indian parent company, Amneal Pharmaceuticals Co. India Pvt. Ltd., have infringed on its patent by asking the U.S. Food and Drug Administration for regulatory approval to make a generic version of the blockbuster drug.

Abbott alleges that the generic infringes U.S....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.